Extend the Life Line…



Sacubitril 24mg + Valsartan 26mg TABLETS


Chronic Heart Failure

  • The first agent approved in a new class of drugs called angiotensin receptor neprilysin inhibitor
  • FDA approved to treat patients with chronic heart failure with reduced ejection fraction
  • Combination performs better than Enalapril across various heart failure patients and shows substantial benefits in patients with other common comorbidities
  • The PARADIGM-HF trial showed that treatment of heart failure with Valsartan/Sacubitril reduced the risk of the first occurrence of either cardiovascular death or HF-related hospitalization by 20% compared with Enalapril
  • More effective for the management of hypertension patients as compared to ARB